Related references
Note: Only part of the references are listed.EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Wendy Beguelin et al.
CANCER CELL (2013)
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity
X. Zhao et al.
LEUKEMIA (2013)
Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia
Deepa Sampath et al.
BLOOD (2012)
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
Wendy Cuccuini et al.
BLOOD (2012)
被撤回的出版物: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas (Retracted article. See vol. 41, pg. 1198, 2023)
Xinwei Zhang et al.
CANCER CELL (2012)
Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis
Sandrine Sander et al.
CANCER CELL (2012)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Roland Schmitz et al.
NATURE (2012)
Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas
X. Zhang et al.
ONCOGENE (2012)
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
Jessica D. Kessler et al.
SCIENCE (2012)
Targeting Synthetic Lethal Interactions between Myc and the eIF4F Complex Impedes Tumorigenesis
Chen-Ju Lin et al.
CELL REPORTS (2012)
MYC and Aggressive B-cell Lymphomas
Graham W. Slack et al.
ADVANCES IN ANATOMIC PATHOLOGY (2011)
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target
Roberta Zappasodi et al.
BLOOD (2011)
PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma
Cristina Gomez-Abad et al.
BLOOD (2011)
Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
Leo Kretzner et al.
CANCER RESEARCH (2011)
Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma
Jonathan H. Schatz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc
Caihua Zhu et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2011)
Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation
Sung-Keum Seo et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Pharmacokinetics, Safety and Inducible Cytokine Responses during a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (Givinostat)
Antonio Furlan et al.
MOLECULAR MEDICINE (2011)
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
W-J Chng et al.
LEUKEMIA (2011)
Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells
T. S. Lewis et al.
LEUKEMIA (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
For better or for worse: the role of Pim oncogenes in tumorigenesis
Martijn C. Nawijn et al.
NATURE REVIEWS CANCER (2011)
Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death
Roberta Zappasodi et al.
CANCER RESEARCH (2010)
Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
Sharon Barrans et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
Nahum Sonenberg et al.
CELL (2009)
Repressing the repressor A new mode of MYC action in lymphomagenesis
Sandrine Sander et al.
CELL CYCLE (2009)
HuR recruits let-7/RISC to repress c-Myc expression
Hyeon Ho Kim et al.
GENES & DEVELOPMENT (2009)
HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells
Rekha Rao et al.
BLOOD (2008)
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a
Sandrine Sander et al.
BLOOD (2008)
Myc-mediated transcriptional repression by recruitment of histone deacetylase
John F. Kurland et al.
CANCER RESEARCH (2008)
c-Myc and eIF4F are components of a feedforward loop that links transcription and translation
Chen-Ju Lin et al.
CANCER RESEARCH (2008)
Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue
Elena Hartmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study
Eric D. Hsi et al.
LEUKEMIA & LYMPHOMA (2008)
Pim kinase-dependent inhibition of c-Myc degradation
Y. Zhang et al.
ONCOGENE (2008)
The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target gene
Yi Wen Kong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells
V. Barbetti et al.
ONCOGENE (2008)
MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells
Valerie B. Sampson et al.
CANCER RESEARCH (2007)
PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation
Alessio Zippo et al.
NATURE CELL BIOLOGY (2007)
Evidence that microRNAs are associated with translating messenger RNAs in human cells
Patricia A. Maroney et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2006)
Phosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entry
Amit Kumar et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
c-Myc inhibition negatively impacts lymphoma growth
I Gomez-Curet et al.
JOURNAL OF PEDIATRIC SURGERY (2006)
Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival
PS Hammerman et al.
BLOOD (2005)
High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults
M Di Nicola et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells
ZR Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
c-MYC: More than just a matter of life and death
S Pelengaris et al.
NATURE REVIEWS CANCER (2002)
Translocations involving c-myc and c-myc function
LM Boxer et al.
ONCOGENE (2001)
Share Paper
